Eupraxia Pharmaceuticals Announces Additional Positive Clinical Data From Phase 1b/2a RESOLVE Trial Evaluating EP-104GI For Eosinophilic Esophagitis (EoE) - Press Release
Eupraxia Pharmaceuticals Announces Additional Positive Clinical Data From Phase 1b/2a RESOLVE Trial Evaluating EP-104GI For Eosinophilic Esophagitis (EoE) - Press Release
Eupraxia Pharmicals 宣布了评估 EP-104GI 用于嗜酸性食管炎 (EoE) 的 1b/2a 期 RESOLVE 试验的更多阳性临床数据-新闻稿
- Trial's first and second cohorts maintaining signs of potential efficacy out to 24 weeks
- Data from the second cohort showed improvements in eosinophil counts and histological scores out to 12 weeks suggesting a dose response over the first cohort
- Data from the trial's third cohort suggest improvements in patient-reported symptoms and histological outcomes at 12 weeks
- EP-104GI showed an encouraging safety profile in all three cohorts
- 试验的第一和第二组在24周内保持潜在疗效的迹象
- 来自第二组队列的数据显示，嗜酸性粒细胞计数和组织学分数均有所改善，达到了12周，这表明与第一组队列相比出现了剂量反应。
- 该试验第三组的数据表明，在12周时，患者报告的症状和组织学结局都有所改善
- EP-104GI 在所有三个队列中均显示出令人鼓舞的安全状况
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。